Sarcoidosis is a systemic granulomatous disease of unknown origin. We herein report a case of sarcoidosis in a chronic dialysis patient diagnosed by hypercalcemia without any common clinical manifestations. The onset of sarcoidosis in chronic dialysis patients is rare; to the best of our knowledge, only 23 cases have been reported. Evaluation of the 23 previously published cases revealed that a diagnosis of sarcoidosis was often achieved by the presence of sarcoidosis-related hypercalcemia without any common clinical presentations, as in the present case. This characteristic may arise from a specific immune deficiency and the unique physiology of 1,25-dihydroxyvitamin D3, a main cause of sarcoidosis-related hypercalcemia, in chronic dialysis patients. These clinical features may be useful to understand the pathogenesis of sarcoidosis.
Introduction
Sarcoidosis is a systemic granulomatous disease of unknown origin. It can affect virtually any organ with diverse manifestations (1) . However, most patients present with typical symptoms that are recognizable at the first clinical encounter. Up to 50% of patients diagnosed with sarcoidosis are asymptomatic, and their condition is often discovered incidentally as a result of bilateral hilar lymphadenopathy (BHL) on chest X-rays. BHL is associated with about 95% of cases of sarcoidosis at diagnosis (2, 4) . Approximately 10% to 20% of patients have bilateral uveitis with blurred vision and photophobia at diagnosis (3, 4) , and about 15% of patients have a skin pathology such as erythema nodosum (EN) at diagnosis (4) . Besides these clinical manifestations, as shown in Table 1 , relatively few patients are diagnosed by cardiac involvement, neurologic symptoms, and hypercalcemia (1, 4) . In terms of nephrologic manifestations, renal failure represented by interstitial nephritis is associated with less than 1% of cases of sarcoidosis (4) . On the other hand, the onset of sarcoidosis has been rarely reported in chronic dialysis patients; as far as we know, only 23 cases have been published (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) . Therefore, nephrologic manifestations of sarcoidosis are considered to be rare, especially in chronic dialysis patients. We herein report a case of sarcoidosis in a chronic dialysis patient diagnosed in the wake of sarcoidosis-related hypercalcemia without the presence of any common systemic clinical manifestations. A review of published cases of sarcoidosis in chronic dialysis patients is also presented, and the pathophysiologic features of these cases are discussed. 23 .3 mg/dL; iPTH, 9.0 pg/mL; parathyroid hormone related protein ( PTHrP ) , < 1.0 pmol / L ; 1,25-dihydroxyvitamin D3, 55.0 pg/mL; angiotensin-converting enzyme (ACE), 21.5 mU/mL; lysozyme, 84.2 μg/mL; and soluble interleukin-2 receptor, 3,737 U/mL. Bone scintigraphy with technetium-99 m methylene diphosphonate did not reveal any abnormal uptake. Radionuclide gallium scintigraphy revealed abnormal uptake in the spleen, a few small mediastinal lymph nodes, and subcutaneous tissue on the outside aspects of both thighs (Fig. 2) . Ophthalmological screening revealed asymptomatic uveitis in only the left eye, although it had not been detected in May 2011. Based on the above findings, he was suspected to have sarcoidosis, but it seemed to be atypical. Therefore, malignant diseases producing 1,25-dihydroxyvitamin D3, such as malignant lymphoma, and other granulomatous diseases such as tuberculosis were considered as differential diagnoses. Although tissue diagnosis is needed for a definitive diagnosis, there were no typical pathological lesions available for biopsy. To establish a definitive diagnosis, we performed a skin biopsy from the outside aspect of his left thigh, where there was abnormal uptake of gallium without any skin manifestations of sarcoidosis. Noncaseating granulomas with multinucleated giant cells were revealed in the tissue biopsy (Fig. 3) . Then we performed a bone-marrow biopsy for the assessment of malignant lymphoma, and no malignant finding was observed. The diagnosis of sarcoidosis was then ascertained. Steroid therapy was considered to treat the hypercalcemia. However, because sarcoidosis-related hypercalcemia generally has the potential to heal spontaneously, and because his hypercalcemia had slightly improved without any therapy after admission, he was discharged from the hospital in September 2011. The hypercalcemia then stabilized to an adjusted calcium level of 10.0 to 11.0 mg/dL for a while. However, his serum ACE and lysozyme levels were generally maintained at high levels, and his hypercalcemia flared again with an elevated serum 1,25-dihydroxyvitamin D3 level in January 2012. The left uveitis also worsened despite local steroid therapy, and uveitis subsequently occurred de novo in the right eye. In January 2012, oral prednisolone (PSL) was administered at 20 mg/day. Within 1 month, the persistent hypercalcemia and bilateral uveitis improved rapidly, and the ACE, lysozyme, and 1,25-dihydroxyvitamin D3 levels simultaneously decreased. The PSL dose was gradually decreased by 5 mg every 4 weeks, then continued at 5 mg/day as a maintenance dose for 1 year. The sarcoidosis has not flared up throughout the follow-up (Fig. 4) .
Discussion
The present case of sarcoidosis in a chronic dialysis patient was diagnosed in the wake of sarcoidosis-related hypercalcemia without the presence of any common systemic clinical manifestations. This case was very difficult to make a diagnosis because of many atypical features as sarcoidosis, lack of common symptoms and elderly onset and so on. Therefore we considered differential diagnoses, especially tuberculosis and malignant lymphoma producing 1,25-dihydroxyvitamin D3. But tuberculosis was interpreted as negative by reasons of negative tuberculin skin test and good response to steroid therapy, and malignant lymphoma was also negative for the sake of pathological findings.
To the best of our knowledge, only 23 cases of sarcoidosis in chronic dialysis patients have been reported (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) . Their clinical characteristics, laboratory data, and treatment are listed in Table 2 . Nineteen of all 23 cases had sarcoidosis-related hypercalcemia with an adjusted serum calcium level of >10.5 mg/dL at diagnosis. Ten of these patients developed sarcoidosis-related hypercalcemia of less than the upper limit of the normal level of serum 1,25-dihydroxyvitamin D3 (60 pg/mL). Eleven patients lacked common systemic clinical manifestations, BHL, uveitis, or EN at diagnosis. Only six patients had BHL, six had uveitis, and two had EN at diagnosis. Nine patients had atypical organ involvement, arthrosis, or muscle, nerve, or bone marrow involvement. Sixteen patients underwent steroid therapy, seven of whom responded well to PSL at <30 mg/day, although a dose of 30 to 40 mg/day is generally recom- (25) . To review these reports, sarcoidosis in chronic dialysis patients is considered to be a rare condition. A diagnosis of sarcoidosis is often provided in the wake of sarcoidosis-related hypercalcemia without the presence of most common clinical manifestations. In such cases, sarcoidosis-related hypercalcemia sometimes improves with relatively low doses of PSL.
In patients with comorbid organ involvement, atypical organ involvement frequently occurs. Notably, however, this review is based on only a few case reports and contains publication bias. We suppose that these clinical features may arise from an unique physiology of 1,25-dihydroxyvitamin D3, a main cause of sarcoidosis-related hypercalcemia, and a specific immune deficiency in chronic dialysis patients.
The mechanism of sarcoidosis-related hypercalcemia is considered to involve 1,25-dihydroxyvitamin D3 produced by macrophages in noncaseating granulomas (26) . In general, 1,25-dihydroxyvitamin D3 is produced in the kidneys, but this extrarenal production of 1,25-dihydroxyvitamin D3 plays a central role in the development of hypercalcemia in patients with sarcoidosis. Various cytokines, especially interferon-γ, released spontaneously from macrophages in noncaseating granulomas, are known to induce 1α-hydroxylase, which catalyzes the conversion of 25-hydroxyvitamin D3 to 1,25-dihydroxyvitamin D3 (27) . Hyperproduction of 1,25-dihydroxyvitamin D3 triggers hypercalcemia because of increased bone resorption and calcium absorption from the gastrointestinal tract, leading to suppression of iPTH. On the other hand, steroid therapy for hypercalcemia is considered to suppress the induction of 1α-hydroxylase in macrophages and lead to normalization of 1,25-dihydroxyvitamin D 3 (28) . Therefore 1,25-dihydroxyvitamin D3 is associated with the activity of sar-coidosis (29) . Indeed, in the present case, the serum concentrations of calcium and iPTH were well linked to the variation in the serum 1,25-dihydroxyvitamin D3 level (Fig. 2) . However, it should be noted that the serum 1,25-dihydroxyvitamin D3 level at the onset of sarcoidosis-related hypercalcemia was within the normal range (20-60 pg/mL). In patients with chronic renal failure, especially during chronic dialysis, the serum 1,25-dihydroxyvitamin D3 level reportedly tends to decrease in proportion to the residual renal function (30) . Under its influence, chronic dialysis patients become more sensitive to 1,25-dihydroxyvitamin D3 than nondialysis patients. Therefore, they often experience hypercalcemia even within the normal range of 1,25-dihydroxyvitamin D3. Thus, we consider that hypercalcemia is strongly associated with sarcoidosis in chronic dialysis patients. We also consider that sarcoidosis-related hypercalcemia appears early in the course of sarcoidosis in chronic dialysis patients. Actually, in the present case, there were no common systemic clinical manifestations without hypercalcemia at diagnosis. Bilateral uveitis, one of the typical findings of sarcoidosis, subsequently developed in a delayed manner.
Then chronic dialysis patients have an impaired immune response that accounts for their susceptibility to infections (31) . The immunodeficiency of chronic dialysis patients results from a disturbance in the function of various cell types involved in immune defenses, including polymorphonuclear leukocytes, monocytes, and T lymphocytes (32) . In such patients, the immunodeficiency of T lymphocytes, especially T-helper lymphocytes 1 (Th1), is important. Although the cause of sarcoidosis is incompletely understood, the pathogenesis of sarcoidosis is considered to involve antigen exposure in a genetically susceptible host, resulting in typical granulomatous inflammation with a prominent Th1-cell-mediated immune response (1) . Therefore, Th1 immunodeficiency in chronic dialysis patients may result in hypoplasia of granulomas. It may also decrease the risk of developing sarcoidosis. Furthermore, because causative antigens are not enclosed by a typical granuloma, they may spread hematogenously throughout the body, potentially leading to atypical organ involvement. We suppose that the few reports of sarcoidosis in chronic dialysis patients may be because it is often difficult to achieve a definitive diagnosis by biopsy. The present case had an absence of typical findings of sarcoidosis. Fortunately, however, a skin biopsy taken from an area of abnormal gallium uptake despite no macroscopic skin abnormalities revealed noncaseating granulomas with multinucleated giant cells. The diagnosis of sarcoidosis was thus ascertained. In such a sense, gallium scintigraphy is often helpful in evaluating the progression of sarcoidosis (33) .
In conclusion, the present report describes a case of sarcoidosis in a chronic dialysis patient diagnosed in the wake of sarcoidosis-related hypercalcemia without the presence of any common systemic clinical manifestations. A review of sarcoidosis in chronic dialysis patients showed that a characteristic of sarcoidosis in chronic dialysis patients is that the diagnosis of sarcoidosis is often achieved in the wake of sarcoidosis-related hypercalcemia without the presence of most common clinical manifestations. This characteristic may arise from the specific immune deficiency and the unique physiology of 1,25-dihydroxyvitamin D3, a main cause of sarcoidosis-related hypercalcemia, in chronic dialysis patients. These clinical features may be useful to understand the pathogenesis of sarcoidosis. Despite the fact that sarcoidosis is a rare condition in chronic dialysis patients, and even when no typical findings of sarcoidosis are present, one should still consider sarcoidosis as a differential diagnosis.
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